Wells Fargo Maintains Overweight on PTC Therapeutics, Lowers Price Target to $93
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and lowers the price target from $95 to $93.
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and lowers the price target from $95 to $93.